AtriCure

Yahoo Finance • 14 days ago

Omeros Gets FDA Approval for YARTEMLEA as First Therapy for TA-TMA

Omeros Corporation OMER recently announced that the FDA approved its YARTEMLEA (narsoplimab-wuug) to treat hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA), a frequent life-threatening condition that can oc... Full story

Yahoo Finance • last month

Is AtriCure Stock a Buy or Sell After a Director Dumped 10,000 Shares?

Key Points AtriCure Board of Directors member Sven Wehrwein sold 10,000 shares in the company on Nov. 24 and 25, 2025. The transaction was valued at nearly $377,000. These 10 stocks could mint the next wave of millionaires › Sven Wehrwei... Full story

Yahoo Finance • 2 months ago

AtriCure raises 2025 revenue outlook to $532M–$534M as product launches propel double-digit growth

Earnings Call Insights: AtriCure (ATRC) Q3 2025 MANAGEMENT VIEW * Michael H. Carrel, CEO, highlighted "a very strong third quarter with total revenue of $134 million, reflecting a 16% increase year-over-year." He cited expanding adopti... Full story

Yahoo Finance • 4 months ago

Do You Believe in the Upside Potential of Atricure (ATRC)?

Riverwater Partners, an investment management company, released its “Small Cap Strategy” Q2 2025 investor letter. A copy of the letter can be downloaded here. The Small Cap Core Strategy underperformed the Russell 2000 in Q2 2025, primaril... Full story

Yahoo Finance • 5 months ago

AtriCure at Canaccord Conference: Innovation Fuels Growth

On Tuesday, 12 August 2025, AtriCure (NASDAQ:ATRC) presented at Canaccord Genuity’s 45th Annual Growth Conference, detailing its strategic initiatives and financial performance. The company highlighted its leadership in AFib and pain manag... Full story

Yahoo Finance • 5 months ago

AtriCure raises 2025 revenue outlook to $527M-$533M with strong Q2 growth and innovation milestones

Earnings Call Insights: AtriCure, Inc. (ATRC) Q2 2025 MANAGEMENT VIEW * Michael H. Carrel, CEO, reported "an outstanding second quarter with total revenue of $136 million, reflecting a 17% year-over-year increase." He highlighted broad... Full story

Yahoo Finance • 5 months ago

What's going on in today's after hours session

Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements. [postmarket] TODAY'S AFTER HOURS GAINERS TICKER CHANGE COMMENT RCON [https://www.chartmill.com/stock/quote/RCON/... Full story

Yahoo Finance • 6 months ago

S&P Futures Gain With Focus on U.S. JOLTs Report and Corporate Earnings, FOMC Meeting on Tap

September S&P 500 E-Mini futures (ESU25 [https://www.barchart.com/futures/quotes/ESU25]) are trending up +0.24% this morning, extending yesterday’s gains, while investors shift their focus from recent U.S. trade deals to economic data, a n... Full story

Yahoo Finance • 2 years ago

Market Today: Boeing Soars on Upgraded Price Target, GameStop Rallies Ahead of Earnings

Improved confidence in the supply chains ability to support strong demand in the aircraft industry has led to a positive outlook for Boeing (NYSE:BA). RBC Capital Markets analyst Ken Herbert has increased the price target for Boeing to $27... Full story

Yahoo Finance • 3 years ago

AtriCure to Participate in the Oppenheimer 33rd Annual Healthcare Conference

MASON, Ohio, February 17, 2023--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today an... Full story

Yahoo Finance • 3 years ago

AtriCure Reports Third Quarter 2022 Financial Results

MASON, Ohio, November 01, 2022--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain managem... Full story

Yahoo Finance • 3 years ago

AtriCure (NASDAQ:ATRC) shareholders have earned a 11% CAGR over the last five years

It might be of some concern to shareholders to see the AtriCure, Inc. (NASDAQ:ATRC) share price down 15% in the last month. Looking further back, the stock has generated good profits over five years. It has returned a market beating 72% in... Full story

Yahoo Finance • 4 years ago

AtriCure to Announce Second Quarter 2022 Financial Results

MASON, Ohio, July 12, 2022--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management... Full story

Yahoo Finance • 4 years ago

Is It Time To Consider Buying AtriCure, Inc. (NASDAQ:ATRC)?

AtriCure, Inc. (NASDAQ:ATRC), might not be a large cap stock, but it saw significant share price movement during recent months on the NASDAQGM, rising to highs of US$66.36 and falling to the lows of US$35.10. Some share price movements can... Full story

Yahoo Finance • 4 years ago

AtriCure Reports First Quarter 2022 Financial Results

MASON, Ohio, May 03, 2022--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management,... Full story